Biodefense BAA renews support of adjuvant development

The National Institute of Allergy and Infectious Diseases plans to renew a Broad Agency Announcement that supports the Adjuvant Development Program in the advancement of novel vaccine adjuvants.

The NIAID's Division of Allergy, Immunology and Transplantation supports extramural research that could develop new products to protect against biological agents. Such agents could be used in acts of bioterrorism, Global Biodefense reports.

The research could also protect the public from diseases such as dengue fever, multi-drug resistant tuberculosis and West Nile Virus.

The BAA supports developing adjuvants through lead compound optimization and immunological characterization studies. The adjuvant vaccine candidates must already be characterized as safe in an animal model, be identified as minimally reactogenic, have documented evidence exhibiting a mechanism of action for the adjuvant, be shown to safely add to the ability of a vaccine to protect against pathogens in an in vivo animal model and show that the adjuvant has immune-enhancing abilities with human tissues or primary cells, according to Global Biodefense.

The government plans to award completion type, multiple cost reimbursement contracts with options starting around August 30.

The NIAID prioritized the biological agents that pose the greatest threats to civilians on its Emerging and Re-emerging Infectious Diseases list.